165890-26-6
Chemical Structure
Asenapine impurity 1
- CAS No.: 165890-26-6
- Formula:C17H14ClNO2
- Molecular Weight:299.76
IUPAC Name: (3aS,12bR)-11-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-1-one
InChIKey: OOUVAHYYJVOIIB-CJNGLKHVSA-N
SMILES: O=C1[C@](C(C=C(Cl)C=C2)=C2OC3=C4C=CC=C3)([H])[C@]4([H])CN1C
Biological Activity: Asenapine impurity 1 is an impurity of Asenapine (HY-10121). Asenapine, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Asenapine impurity 1 | 95.0% | Asenapine impurity 1 is an impurity of Asenapine (HY-10121). Asenapine, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Asenapine impurity 1 (Standard) | ≥98% | rel-(3aR,12bS)-11-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-1-one (Standard) is the analytical standard of rel-(3aR,12bS)-11-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-1-one. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. [Content Brief]
- [2]. Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. [Content Brief]
